Brenntag shares slip as Barclays warns of likely earnings guidance cut

Brenntag shares dipped after Barclays warned of a likely earnings guidance cut, citing deteriorating macroeconomic conditions and weakening U.S. demand, which disproportionately impacts Brenntag due to its higher industrial chemicals exposure. The brokerage significantly lowered its Q2 EBITA estimate to €263 million and its 2025 EBITA forecast by 4.7% to €1.06 billion, highlighting the company's comparative weakness against peers and the potential for another downward revision with Q2 results on August 13. Despite the grim outlook, Barclays maintained an "equal weight" rating and a €70 price target, suggesting much of the pessimism may already be priced into the stock.

Analysis

Barclays has issued a cautionary outlook on Brenntag, forecasting a probable cut to the company's earnings guidance due to deteriorating macroeconomic indicators and weakening demand, particularly in the U.S. market where customers are delaying purchases ahead of potential tariff announcements. The brokerage slashed its Q2 EBITA estimate for Brenntag to €263 million, 3.1% below consensus, and revised its forecast for Q2 organic gross profit from 0.6% growth to a 3.1% contraction. This weakness is amplified by Brenntag's higher exposure to industrial chemicals through its Essentials segment, leading it to underperform peers like IMCD, which is still forecast for 2.6% growth. Barclays' 2025 EBITA forecast of €1.06 billion now sits below the lower bound of Brenntag's own guidance, signaling a high risk of a downward revision with Q2 results on August 13, which would mark the second consecutive year of such cuts. Despite these headwinds, Barclays maintains an 'equal weight' rating and a €70 price target, implying 22.9% upside, and notes that significant pessimism may already be priced into the stock, a view supported by a strong 42.4% projected growth in 2025 free cash flow and declining net debt.

Key Decisions for Investors

• Investors should exercise caution ahead of the August 13 earnings report, as a likely downward guidance revision could lead to further near-term price volatility.
• Consider the company's relative underperformance against peers like IMCD as a potential basis for a pairs trade strategy within the European specialty chemicals sector.
• For those with a higher risk tolerance, the combination of a low valuation at 14.3x 2025 earnings, a high price target, and strong free cash flow projections could present a contrarian entry point if the view is that negative sentiment is already fully priced in.
• Closely monitor management's commentary on U.S. demand and the impact of tariff uncertainty in the upcoming report, as any signs of stabilization in these areas could serve as a major positive catalyst.